Medicus Pharma gains independent validation for SkinJect Phase 2 data

Purepoint Uranium Group CEO Chris Frostad joined Steve Darling from Proactive to discuss the company’s latest uranium exploration progress at its Dorado project in northern Saskatchewan, as well as the broader process of making and advancing a discovery. Frostad explained that Purepoint Uranium Group operates in one of the world’s most prolific uranium regions, collaborating with major partners including Cameco, Orano, and ISOEnergy. The discussion focused on the company’s recent discovery at the Dorado project, particularly within the Nova zone, where initial drilling intersected high-grade uranium mineralization. Highlighting that discovery is only the first step, Frostad noted: “The real work happens after the fact,” emphasizing the importance of follow-up drilling to confirm whether mineralization is repeatable and to better understand the structure and controls of the deposit. The company is now conducting additional drilling to expand on the initial findings and determine the direction and continuity of the uranium system. Frostad also outlined how modern exploration relies heavily on geophysics and geological modelling. He explained that uranium itself is not directly detectable through geophysical surveys; instead, the company analyzes surrounding rock types, structures, and alteration patterns to guide drilling decisions and refine its exploration model. With ongoing work at Dorado, Purepoint Uranium Group aims to define the scale and orientation of the mineralized system and determine the next steps for continued exploration. #proactiveinvestors #purepointuraniumgroup #tsxv #ptu #otcqb #ptuuf #UraniumExploration #DoradoProject #NorthernSaskatchewan #HighGradeUranium #MiningDiscovery #Geophysics #MineralExploration #Cameco #Orano #ISOEnergy #ResourceDevelopment #SustainableEnergy #NuclearFuel #ExplorationUpdate

American Resources Corp CFO Kirk Taylor joined Steve Darling from Proactive to announce a strategic collaboration with Mitsubishi Materials Corporation, a global leader in advanced materials and resource circulation. The partnership includes a strategic investment in ReElement Technologies, reinforcing confidence in its refining-first platform and its role in strengthening critical mineral supply chains. Taylor explained that the collaboration is designed to accelerate the development of scalable and economically viable refining solutions across the United States and allied nations. In the U.S., the partnership will focus on supporting ReElement’s refining operations through feedstock sourcing, tolling arrangements, and offtake opportunities—key components in expanding domestic refining capacity. In Japan, the companies will jointly explore opportunities to commercialize rare earth and critical mineral recycling solutions. This effort will combine MMC’s well-established recycling infrastructure with ReElement’s proprietary chromatographic refining platform, creating a powerful synergy aimed at improving efficiency and sustainability in the sector. ReElement’s refining-first approach is built for flexibility, allowing it to process both recycled and primary feedstocks into high-purity materials. This capability positions the company as a scalable solution to the global midstream refining gap, a critical bottleneck in the supply chain for rare earth elements and other essential minerals. Unlike conventional solvent-based refining methods—which are often difficult to implement outside of China due to environmental, capital, and operational challenges—ReElement’s platform offers a modular, cost-effective, and environmentally responsible alternative. He also անդրscored the importance of samarium, a critical element used in defence-related magnet applications, emphasizing the company’s role in supporting secure and resilient supply chains for the US and allied nations. Taylor noted that American Resources Corp has built a flexible mineral refinement platform capable of adapting to evolving customer needs and addressing new challenges across the sector. #proactiveinvestors #americanresourcescorporation #nasdaq #arec #SustainableMining, #MineralRefining, #RecyclingInnovation, #CriticalMinerals, #ReElement #MitsubishiMaterials #CriticalMinerals #RareEarths #SupplyChain #EnergyTransition #AdvancedMaterials #RecyclingInnovation #MiningTech #SustainableSolutions #USManufacturing #JapanInnovation #ResourceSecurity #CleanTech

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive Medicus Pharma CEO Dr. Raza Bokhari joined Steve Darling from Proactive to report independent clinical validation of the company’s Phase 2 SkinJect® dataset by Dr. Babar Rao, principal investigator of the SKNJCT-003 study and a globally recognized leader in dermatology and skin cancer research. According to Dr. Rao’s independent assessment, the study results are clinically meaningful and “decision-grade,” supporting Medicus Pharma’s continued development of the SkinJect platform and future regulatory engagement. His validation adds significant credibility to the dataset as the company advances toward later-stage trials. The SKNJCT-003 trial is a randomized, double-blind, three-arm Phase 2 study designed to evaluate microneedle-mediated delivery of doxorubicin in patients with nodular basal cell carcinoma. The study compares the therapeutic approach against a biologically active device-only control, providing a rigorous framework to isolate the incremental benefit of the drug component while also assessing both visual (clinical) and histological clearance endpoints. Dr. Rao emphasized that the trial design enables a clear understanding of treatment effectiveness, combining real-world clinical observations with detailed pathological analysis. He noted that the findings carry important implications for patient care, particularly in reducing reliance on invasive procedures. One of the most compelling outcomes highlighted was that approximately three out of four treated lesions achieved visual tumor clearance. This suggests that a significant number of patients could potentially avoid immediate surgical intervention, offering a less invasive treatment alternative for certain forms of skin cancer. Dr. Rao, a dermatologist, dermatopathologist, Mohs surgeon, and clinical investigator, brings extensive expertise in skin oncology. He serves as Professor of Dermatology and Pathology and Director of Clinical Research at Rutgers Robert Wood Johnson Medical School, with additional academic roles at Weill Cornell Medical College and California Health Sciences University. The independent validation strengthens Medicus Pharma’s position as it continues to develop SkinJect as a novel, minimally invasive treatment option, with the potential to reshape how certain skin cancers are managed in clinical practice #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #SkinJect #ClinicalTrials #Phase2 #Dermatology #SkinCancer #BasalCellCarcinoma #OncologyInnovation #Biotech #DrugDelivery #Microneedle #Doxorubicin #ClinicalResearch #HealthcareInnovation #MedicalBreakthrough #ProactiveInvestors

Miivo Holdings CEO Alex Damouni joined Steve Darling from Proactive to share news to highlight the company’s AI-powered platform designed to help small and medium-sized businesses identify early warning signs and improve operational performance. Damouni explained that Miivo brings together financial, operational, and customer data into a single, unified platform, giving business owners a real-time, consolidated view of their company. By leveraging artificial intelligence, the system identifies potential issues early and delivers prioritized, tailored recommendations. “What Miivo is, it's an AI-powered platform that detects these early warning problems about your business by pulling information from different sources,” he said. The platform is built to serve two core segments: businesses facing financial or operational challenges, and more established companies seeking to streamline workflows, automate manual processes, and scale more efficiently. Damouni emphasized that Miivo’s flexible approach is designed to “meet you where you are,” offering both self-service tools and more comprehensive managed solutions. To expand accessibility, the company recently launched its Miivo Starter plan, enabling smaller businesses to adopt the platform independently at a lower cost entry point. At the same time, Miivo continues to offer customized, hands-on support for clients requiring deeper integration and guidance. Looking ahead, Miivo is executing a dual growth strategy that includes developing additional self-service offerings and pursuing a strategic acquisition to broaden its geographic reach and increase recurring revenue. The platform is already gaining traction globally, with users across North America, Europe, the Middle East, and India. With its focus on AI-driven insights, automation, and data integration, Miivo is positioning itself as a powerful tool for businesses aiming to proactively manage risk, enhance decision-making, and drive sustainable growth. #proactiveinvestors #miivoholdings #tsxv #mivo #AIForBusiness #BusinessIntelligence #SMBTech #OperationalExcellence #DataDriven #AIAutomation #EarlyWarningSystem #FinancialInsights #WorkflowOptimization #BusinessGrowth #TechInnovation #GlobalExpansion #RiskManagement #SaaSPlatform

Reconnaissance Energy Africa or ReconAfrica CEO Brian Reinsborough joined Steve Darling from Proactive to announce the commencement of production testing operations at the Kavango West 1X discovery well, marking a key step forward in the company’s exploration and development efforts. Reinsborough confirmed that testing operations have begun on schedule following receipt of all necessary regulatory permits. Work crews are now on site preparing the well, with critical equipment—including a production liner sourced from North America—already delivered. The company has also secured contracts with major oilfield service providers Halliburton and Schlumberger Oilfield Services, alongside engaging local suppliers to support operations. Ongoing analysis has further strengthened the project’s outlook. Incorporating additional rock data and updated log analysis, ReconAfrica has refined its petrophysical interpretation, now identifying 74 metres (246 feet) of net hydrocarbon pay in the Huttenberg formation—an increase from the previously reported 64 metres (210 feet). This improvement highlights the growing potential of the discovery as technical understanding of the reservoir advances. As operator, the company plans to conduct production testing across six optimized zones, including three within the Huttenberg formation and three in the deeper Elandshoek formation. In total, approximately 345 metres (1,132 feet) of prospective interval will be isolated and perforated for testing, providing a comprehensive evaluation of the well’s production capabilities. Beyond Namibia, Reinsborough also provided an update on the company’s activities in Gabon, specifically within the Ngulu block. ReconAfrica is currently reprocessing 3D seismic data across key areas, including the Loba oil discovery. Upon completion, the company intends to select an appraisal drilling location and commission a third-party resource report, expected by the end of 2026. The Ngulu block spans approximately 1,214 square kilometres in shallow offshore waters of central Gabon and is strategically positioned near several producing oil fields. The asset includes the Loba discovery and more than 28 identified prospects across both pre-salt and post-salt plays, underscoring its significant exploration upside. Overall, the initiation of production testing at Kavango West, combined with ongoing evaluation work in Gabon, positions ReconAfrica to further define its resource base and advance toward potential development opportunities across its portfolio. #proactiveinvestors #reconnaissanceenergyafricaltd #tsxv #reco #otcqx #recaf #NamibiaOil #EnergyExploration #OilAndGas #ExplorationFinancing #Oversubscribed #NamibiaEnergy #KavangoBasin #GabonOffshore #NguluBlock #LobaDiscovery #SeismicReprocessing #AppraisalDrilling #StrategicInvestor #BWEnergy #EnergyMarkets #UpstreamEnergy #ProactiveInvestors

Cuentas CEO Shalom Arik Maimon joined Steve Darling from Proactive to announce that the company’s subsidiary, World Mobile Media Group (WMMG), is launching a next-generation decentralized media platform aimed at transforming how digital content is created, distributed, and monetized. The WMMG platform is designed as a mobile-first, decentralized entertainment ecosystem that brings together premium content, global distribution, and direct-to-consumer monetization. It will feature a curated mix of licensed and original programming, including live streaming events, music performances, and creator-driven content, all delivered through an interactive and community-powered user experience. Unlike traditional streaming services, WMMG is built to prioritize creator empowerment. The platform enables content creators to retain ownership of their work while participating directly in revenue generation, offering greater transparency and control over monetization. At the same time, audiences are given new ways to engage with content and creators, fostering deeper connections and more dynamic digital communities. The launch marks a significant step in Cuentas’ strategic expansion into digital media and next-generation entertainment. By integrating decentralized technologies with its own distribution infrastructure, WMMG aims to create a scalable ecosystem that enhances global access to premium content while redefining how creators are compensated. Looking ahead, the company plans to provide additional updates on the platform’s rollout, including content partnerships and international market expansion, as it works to establish WMMG as a disruptive force in the evolving digital media landscape. #proactiveinvestors #cuentasinc #otcqb #cuen #shalomarikmaimon #Cuentas #WMMG #DigitalMedia #Streaming #ContentCreators #Web3 #Decentralization #Entertainment #Innovation #MediaTech

First Phosphate Corp. CEO John Passalacqua joined Steve Darling from Proactive to announce the successful completion of the company’s infill drill program at its Bégin-Lamarche property in Saguenay–Lac-St-Jean, Quebec. Passalacqua said the drilling campaign, which began in October 2025, confirmed extensive and continuous phosphate mineralization across the existing resource horizon. The program also led to the discovery of two new phosphate intersections in both the Northern and Southern Zones, located on the eastern extension of the known mineralized area—highlighting the project’s potential for further expansion. In response to these encouraging results, the company expanded its original 30,000-metre drill program by an additional 10,000 metres. The expanded drilling was designed to better define the newly identified zones and to test for deeper mineralization across multiple areas within both the Northern and Southern Zones. In total, approximately 40,000 metres of drilling have now been completed. First Phosphate is currently processing the full dataset, with results expected to support an updated geological model for the Bégin-Lamarche property in the coming weeks. This updated model is anticipated to enhance the company’s understanding of the scale, continuity, and grade distribution of the deposit. In addition to the operational update, the company announced a key leadership transition. Gilles Laverdiere will retire as Chief Geologist after an impressive 48-year career in the mining industry. He will be succeeded by Steeve Lavoie, P.Geo., who brings more than 20 years of mineral exploration experience, including recent work with Agnico Eagle Mines. Lavoie joined First Phosphate in November 2025 and is expected to play a key role in advancing the company’s exploration strategy moving forward. The completion of this expanded drill program and the strengthening of the technical team position First Phosphate to advance Bégin-Lamarche as a significant phosphate asset within Quebec’s growing critical minerals sector. #proactiveinvestors #firstphosphatecorp #cse #phos #otcqx #frspf #frspf #BeginLamarche #QuebecMining #Phosphate #CriticalMinerals #DrillResults #MineralExploration #ResourceExpansion #SaguenayLacStJean #MiningNews #BatteryMaterials #Fertilizer #Geology #ExplorationSuccess

Rainbow Rare Earths Ltd (LSE:RBW, OTC:RBWRF, FRA:RR1) CEO George Bennett talked with Proactive's Stephen Gunnion about the company’s £11.1 million fundraising and the strategic significance of bringing Traxys on board as a partner linked to the US government’s Project Vault initiative. Bennett explained how this development positions Rainbow as “a major player in the rare earths market” outside China, highlighting the company’s focus on extracting rare earth elements from phosphogypsum waste residues rather than traditional mining. This approach underpins two key assets: the Phalaborwa Project in South Africa and the Uberaba Project in Brazil. He outlined that the newly secured funding provides a strong financial runway, enabling Rainbow to complete a definitive feasibility study at Phalaborwa by the end of 2026, alongside a pre-feasibility study at Uberaba in partnership with Mosaic. These milestones are expected to be critical value drivers for shareholders. Bennett also emphasised the company’s cost advantage, noting that removing mining and processing steps could make Rainbow one of the lowest-cost producers of separated rare earth oxides. He added that both projects are targeting relatively near-term production, with Phalaborwa expected online in 2029 and Uberaba in 2030. The interview also touches on the strategic opportunity presented by US efforts to build critical mineral stockpiles, positioning Rainbow within a rapidly evolving global supply chain landscape. For more insights like this, visit Proactive’s YouTube channel, like this video, subscribe, and enable notifications so you never miss an update. #RainbowRareEarths #RareEarths #CriticalMinerals #MiningStocks #Phalaborwa #Uberaba #EnergyTransition #USProjectVault #ResourceInvesting #CleanEnergyMaterials #MiningNews #ProactiveInvestors

Digitalbox PLC (AIM:DBOX, FRA:RLXB) CEO James Carter talked with Proactive's Stephen Gunnion about the company’s 2025 results, highlighting a year of growth despite a mixed media market backdrop. Carter explained that Digitalbox expanded its portfolio to ten operating assets through its “verticals program,” launching new products in targeted editorial spaces. The company delivered a 7% increase in revenue, outperforming broader market trends, while adjusted EBITDA rose by 10%. He noted that social media remains a key driver, with Digitalbox growing its total following by 31% to approximately 27 million users. A major shift in strategy has been the company’s evolving monetisation approach. Carter said: “We grew our platform monetisation by 100% in the past year,” reflecting a stronger focus on platform-based audiences and diversified revenue streams. Digitalbox is also moving beyond pure programmatic advertising, with growing contributions from direct-to-consumer offerings such as paid subscriptions. Looking ahead, the company aims to sustain its momentum through new product launches and potential acquisitions. Carter outlined the ambition “to build ourselves into an entertainment powerhouse,” with upcoming launches including Film Shrine, building on the success of existing brands like Reality Shrine. For more insights and interviews like this, visit Proactive’s YouTube channel, like this video, subscribe, and enable notifications so you never miss an update. #Digitalbox #JamesCarter #MediaStocks #DigitalMedia #AdTech #ProgrammaticAdvertising #SocialMediaGrowth #InvestorNews #UKStocks #SmallCapStocks #MediaIndustry #BusinessGrowth #MergersAndAcquisitions #YouTubeFinance #ProactiveInvestors

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) CEO Jeremy Skillington talked with Proactive's Stephen Gunnion about the company securing its first national patent for POLB-001 targeting cancer immunotherapy-induced cytokine release syndrome (CRS). Skillington explained that the patent, granted by IP Australia, covers the use of p38 MAPK inhibitors, including POLB-001, to prevent and treat CRS. He highlighted that the protection is broad and supported by proprietary data generated by the company, following a thorough examination process. The patent marks an important milestone as Poolbeg continues expanding into oncology, building on earlier filings made in the UK and through international patent cooperation frameworks. He noted the timing aligns well with upcoming clinical developments, with interim data from its clinical trial expected in the summer. Skillington said: “The timing of this is absolutely perfect,” emphasising how the patent strengthens the company’s position as it advances the programme. The discussion also outlined why intellectual property is critical for large pharmaceutical partners. Skillington explained that strong patent protection provides exclusivity and reduces uncertainty, which is essential given the significant investment required to bring drugs to market. He added that Poolbeg aims to leverage this growing IP portfolio to support future partnering opportunities. Looking ahead, the company plans to expand patent coverage into additional jurisdictions while progressing its clinical programme and delivering near-term milestones. For more videos like this, visit Proactive’s YouTube channel, like this video, subscribe, and enable notifications so you never miss an update. #PoolbegPharma #POLB001 #BiotechNews #PharmaInnovation #CancerImmunotherapy #CRS #DrugDevelopment #ClinicalTrials #BiotechInvesting #IntellectualProperty #PharmaPartnerships #LifeSciences #HealthcareInnovation #OncologyResearch #BiotechStocks